関連する実験動画
Updated: Jul 13, 2026

20:16
Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
外因的なエストロゲンのプロゲスタゲン補充と子宮内膜がんのリスク
Lancet (London, England)
|August 3, 1991
まとめ
プロゲスタゲンの使用は,特に1サイクルにつき10日以上の使用は,閉経後の女性において,長期にわたってエストロゲン無阻害療法に関連した子宮内膜がんのリスクの増加を大幅に軽減します.
科学分野:
- 婦人科 婦人科について
- 腫瘍学 腫瘍学
- エピデミオロジー エピデミオロジー
背景:
- 外因性プロゲスタゲンの子宮内膜への利点は確立されていますが,子宮内膜がんのリスクについては完全に定量化されていません.
- プロゲスタゲンの利点と,乳がんや心血管疾患の潜在的なリスクとのバランスを取らなければならない.
- エストロゲン誘発性子宮内膜がんを緩和するプロゲスタゲンの役割を理解することは,ホルモン療法の管理に不可欠です.
研究 の 目的:
- ホルモン療法を用いる女性の子宮内膜がんに対するプロゲスタゲン使用の保護効果を定量化するために.
- プロゲスタゲンの使用期間と子宮内膜がんリスクの間の用量反応関係を評価する.
主な方法:
- 158人の子宮内膜がん患者と182人の対照群 (40~64歳の女性) を対象とした集団ベースの症例対照研究.
- エストロゲンとプロゲスタゲンを含むホルモン療法の使用に関する詳細なインタビューを通じてデータ収集.
- 異なるホルモン療法に関連した子宮内膜がんの相対リスク (RR) と信頼区間 (CI) を計算するための統計分析.
主要な成果:
- 3年以上エストロゲンを使用した女性は,使用しなかった女性と比較して子宮内膜がんのリスクが5.7倍増加しました.
- 少なくとも6ヶ月間,同時にプロゲスタゲンを使用すると,このリスクはRR1.6.6に減少しました.
- プロゲスタゲンを1サイクル10日以上使用すると,10日未満 (2.4) と比較してRR (1.1) が著しく低下しました.
結論:
- プロゲスタゲンの使用は,特に1サイクルにつき10日以上は,長期の閉経後のエストロゲン療法に関連した子宮内膜がんのリスクの増加を効果的に軽減します.
- これらの発見は,子宮内膜の安全性を改善するために,併用ホルモン療法 (エストロゲンとプロゲスタゲン) の使用を支持しています.
- 将来の研究は,他の潜在的なリスクを最小限に抑えながら子宮内膜の保護を最大限にするために最適なプロゲスタゲンレジメントを探索することができます.
関連する概念動画
Spermatogenesis
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male reproductive...
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Gonadal and Placental Hormones
The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...

